TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Entrada Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.82+0.45 (+10.30%)
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.05 (−17.89%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Entrada Therapeutics, Inc. saw revenue fall 94.1% to $4.69M over the twelve months to Jun 30, 2026. Free cash flow was -$134.35M.
Revenue
$4.69M
-94.1% vs. a year earlier
Operating income
-$176.53M
TTM Q2 2026
Free cash flow
-$134.35M
TTM Q2 2026
EPS, diluted
-$3.96
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $203.51M
- P/E ratio
- –
- Price to sales
- 43.43
- Price to book
- 0.87
- Dividend yield
- –
- Free cash flow yield
- -66.02%
Fundamentals
- Revenue
- $4.69M
- Net income
- -$165.78M
- EPS, diluted
- -$3.96
- Free cash flow
- -$134.35M
- Book value per share
- $5.53
- Diluted shares
- 42M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$4.69M-94.1% YoY
Operating income
-$176.53M
Net income
-$165.78M
EPS, diluted
-$3.96
Free cash flow
-$134.35M
Reported periodTrailing twelve months